A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies (NCT06645886)
A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KQB198 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hematologic Malignancies
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that
Who can join: Review the eligibility criteria below.
Location: University of California, San Francisco (UCSF) — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (29 Sites)
Showing the first 25 of 29 sites.
- University of California, San Francisco (UCSF) — San Francisco, California
- Colorado Blood Cancer Institute — Denver, Colorado
- Moffitt Cancer Center — Tampa, Florida
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
- Duke University Medical Center — Durham, North Carolina
- Oncology Hematology Cincinnati — Cincinnati, Ohio
- Sarah Cannon Research Institute (SCRI) - Transplant and Cellular Therapy Operations — Nashville, Tennessee
- Texas Oncology Austin Central — Austin, Texas
- MD Anderson Cancer Center — Houston, Texas
- Virginia Cancer Specialists — Fairfax, Virginia
- CHRU de Tours - Hopital Bretonneau — Tours, Centre-Val de Loire
- AP-HM - Hopital de la Timone — Marseille,
- Medizinische Hochschule Hannover (MHH) — Hanover, Lower Saxony
- Universitaetsklinikum Jena — Jena, Thuringia
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola — Bologna, Bologna
- Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore — Rome, Lazio
- ASST Grande Ospedale Metropolitano Niguarda — Milan, Lombardy
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano — Milan, Milan, Lombardy
- Stichting Radboud Universitair Medisch Centrum — Nijmegen, Gelderland
- Aidport Sp. z o.o. — Poznan, Greater Poland Voivodeship
- Copernicus PL Sp. z o.o., Wojewodzkie Centrum Onkologii — Gdansk, Pomeranian Voivodeship
- Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii — Gdansk, Pomeranian Voivodeship
- Pratia Onkologia Katowice — Katowice, Silesian Voivodeship
- Hospital Regional Universitario de Malaga — Málaga, Andalusia
- Institut Catala d'Oncologia - L'Hospitalet — L'Hospitalet de Llobregat, Catalonia
📞 Contact the Study Coordinator
Phone: (877) 827-3222
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hematologic Malignancies
- Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation — New York, New York
- Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device — Milwaukee, Wisconsin
- A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant — Basking Ridge, New Jersey
- Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy — Duarte, California
- PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) — Duarte, California
Explore by condition: All Hematologic Malignancies clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.